(MGTX) MeiraGTx Holdings - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 871m USD | Total Return: 74.2% in 12m

Gene Therapies, Viral Vectors, Genetic Medicines, Riboswitch Platforms
Total Rating 34
Safety 26
Buy Signal -0.33
Biotechnology
Industry Rotation: -12.2
Market Cap: 871M
Avg Turnover: 5.86M
Risk 3d forecast
Volatility66.6%
VaR 5th Pctl11.1%
VaR vs Median0.75%
Reward TTM
Sharpe Ratio1.17
Rel. Str. IBD83.2
Rel. Str. Peer Group57.8
Character TTM
Beta1.679
Beta Downside1.988
Hurst Exponent0.426
Drawdowns 3y
Max DD55.39%
CAGR/Max DD0.22
CAGR/Mean DD0.49
EPS (Earnings per Share) EPS (Earnings per Share) of MGTX over the last years for every Quarter: "2021-03": -0.54, "2021-06": -0.46, "2021-09": -0.59, "2021-12": -0.22, "2022-03": -0.7, "2022-06": -0.76, "2022-09": -0.83, "2022-12": -0.6, "2023-03": -0.62, "2023-06": -0.53, "2023-09": -0.74, "2023-12": -0.42, "2024-03": -0.32, "2024-06": -0.76, "2024-09": -0.55, "2024-12": -0.5, "2025-03": -0.51, "2025-06": -0.48, "2025-09": -0.62, "2025-12": 0.19, "2026-03": -0.57,
EPS CAGR: 27.79%
EPS Trend: 51.0%
Last SUE: -0.38
Qual. Beats: 0
Revenue Revenue of MGTX over the last years for every Quarter: 2021-03: 4.595, 2021-06: 5.116, 2021-09: 6.947, 2021-12: 21.043, 2022-03: 5.633, 2022-06: 10.759, 2022-09: 4.816, 2022-12: -5.288, 2023-03: 3.334, 2023-06: 3.54, 2023-09: 5.103, 2023-12: 2.04, 2024-03: 0.697, 2024-06: 0.282, 2024-09: 10.91, 2024-12: 21.39, 2025-03: 1.926, 2025-06: 3.691, 2025-09: 0.41, 2025-12: 75.364, 2026-03: 0.293,
Rev. CAGR: -61.74%
Rev. Trend: 13.5%
Last SUE: -0.62
Qual. Beats: 0

Warnings

Negative Equity with losses - insolvent profile

Interest Coverage Ratio -8.8 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: MGTX MeiraGTx Holdings

MeiraGTx Holdings PLC (MGTX) is a clinical-stage biotechnology firm specializing in gene therapies for ocular, neurodegenerative, and salivary gland disorders. The company’s pipeline utilizes Adeno-Associated Virus (AAV) vectors to deliver genetic material to target cells, a standard delivery mechanism in the genetic medicines sector designed to provide long-term therapeutic effects from a single administration. Key clinical assets include treatments for Parkinson’s disease, achromatopsia, and radiation-induced xerostomia.

The business model relies heavily on strategic partnerships to fund high-cost research and development, evidenced by collaborations with Johnson & Johnson and Hologen Limited. These agreements typically provide the company with milestone payments and shared commercialization rights. Beyond specific disease targets, MeiraGTx is developing a proprietary riboswitch platform, which allows for precise, small-molecule control over gene expression levels.

For a detailed breakdown of the companys clinical milestones and valuation metrics, consider reviewing the data on ValueRay. Founded in 2015 and headquartered in New York, the company operates within the high-risk, high-reward gene therapy landscape where regulatory approval hinges on demonstrating both long-term safety and durable efficacy in small patient populations.

Headlines to Watch Out For
  • Clinical trial data readouts for Parkinson’s disease candidate AAV-GAD drive valuation
  • Milestones from Johnson & Johnson partnership provide critical non-dilutive capital
  • FDA regulatory approval timeline for inherited retinal disease therapies dictates market entry
  • Manufacturing scale-up costs for proprietary viral vector platforms impact cash runway
  • Expansion of riboswitch technology platform facilitates high-value pharmaceutical licensing agreements
Piotroski VR‑10 (Strict) 3.0
Net Income: -120.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.01 > 0.02 and ΔFCF/TA 47.95 > 1.0
NWC/Revenue: -100.2% < 20% (prev 79.74%; Δ -180.0% < -1%)
CFO/TA 0.03 > 3% & CFO 8.28m > Net Income -120.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 0.55 > 1.5 & < 3
Outstanding Shares: last quarter (81.3m) vs 12m ago 2.87% < -2%
Gross Margin: 91.64% > 18% (prev 0.18%; Δ 9.15k% > 0.5%)
Asset Turnover: 34.04% > 50% (prev 15.40%; Δ 18.63% > 0%)
Interest Coverage Ratio: -8.82 > 6 (EBITDA TTM -93.1m / Interest Expense TTM 12.0m)
Altman Z'' -15.00
A: -0.33 (Total Current Assets 96.2m - Total Current Liabilities 176.1m) / Total Assets 244.7m
B: -3.53 (Retained Earnings -862.5m / Total Assets 244.7m)
C: -0.45 (EBIT TTM -105.9m / Avg Total Assets 234.3m)
D: -2.85 (Book Value of Equity -862.5m / Total Liabilities 302.8m)
Altman-Z'' Score: -19.66 = D
Beneish M -3.99
DSRI: 0.27 (Receivables 3.26m/5.22m, Revenue 79.8m/34.5m)
GMI: 0.19 (GM 91.64% / 17.73%)
AQI: 0.94 (AQ_t 0.04 / AQ_t-1 0.05)
SGI: 2.31 (Revenue 79.8m / 34.5m)
TATA: -0.53 (NI -120.5m - CFO 8.28m) / TA 244.7m)
Beneish M-Score: -3.99 (Cap -4..+1) = AAA
What is the price of MGTX shares? As of May 21, 2026, the stock is trading at USD 9.58 with a total of 778,732 shares traded.
Over the past week, the price has changed by -3.91%, over one month by -9.02%, over three months by +28.59% and over the past year by +74.18%.
Is MGTX a buy, sell or hold? MeiraGTx Holdings has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MGTX.
  • StrongBuy: 3
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the MGTX price?
Analysts Target Price 28 192.3%
MeiraGTx Holdings (MGTX) - Fundamental Data Overview as of 17 May 2026
P/E Forward = 1.6147
P/S = 10.9146
P/B = 225.3073
Revenue TTM = 79.8m USD
EBIT TTM = -105.9m USD
EBITDA TTM = -93.1m USD
Long Term Debt = 49.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.26m USD (from shortTermDebt, last quarter)
Debt = 51.9m USD (corrected: LT Debt 49.7m + ST Debt 2.26m)
Net Debt = -19.6m USD (recalculated: Debt 51.9m - CCE 71.5m)
Enterprise Value = 850.9m USD (870.5m + Debt 51.9m - CCE 71.5m)
Interest Coverage Ratio = -8.82 (Ebit TTM -105.9m / Interest Expense TTM 12.0m)
EV/FCF = -363.2x (Enterprise Value 850.9m / FCF TTM -2.34m)
FCF Yield = -0.28% (FCF TTM -2.34m / Enterprise Value 850.9m)
FCF Margin = -2.94% (FCF TTM -2.34m / Revenue TTM 79.8m)
Net Margin = -151.1% (Net Income TTM -120.5m / Revenue TTM 79.8m)
Gross Margin = 91.64% ((Revenue TTM 79.8m - Cost of Revenue TTM 6.67m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.48 (Enterprise Value 850.9m / Total Assets 244.7m)
Interest Expense / Debt = 5.48% (Interest Expense 2.85m / Debt 51.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -83.6m (EBIT -105.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.55 (Total Current Assets 96.2m / Total Current Liabilities 176.1m)
 Debt / Equity = -0.89 (negative equity) (Debt 51.9m / totalStockholderEquity, last quarter -58.1m)
 Debt / EBITDA = 0.21 (negative EBITDA) (Net Debt -19.6m / EBITDA -93.1m)
 Debt / FCF = 8.36 (negative FCF - burning cash) (Net Debt -19.6m / FCF TTM -2.34m)
 Total Stockholder Equity = -25.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.44% (Net Income -120.5m / Total Assets 244.7m)
 RoE = 474.9% (negative equity) (Net Income TTM -120.5m / Total Stockholder Equity -25.4m)
 RoCE = -435.6% (out of range, set to none) (EBIT -105.9m / Capital Employed (Equity -25.4m + L.T.Debt 49.7m))
 RoIC = -140.4% (out of range, set to none) (NOPAT -83.6m / Invested Capital 59.6m)
 WACC = 11.46% (E(870.5m)/V(922.5m) * Re(11.89%) + D(51.9m)/V(922.5m) * Rd(5.48%) * (1-Tc(0.21)))
Discount Rate = 11.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.57 | Cagr: 13.64%
 [DCF] Fair Price = unknown (Cash Flow -2.34m)
 EPS Correlation: 51.04 | EPS CAGR: 27.79% | SUE: -0.38 | # QB: 0
Revenue Correlation: 13.51 | Revenue CAGR: -61.74% | SUE: -0.62 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.57 | Chg30d=+8.80% | Revisions=-33% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.57 | Chg30d=+19.04% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-2.31 | Chg30d=-41.05% | Revisions=+0% | GrowthEPS=-62.9% | GrowthRev=-97.4%
EPS next Year (2027-12-31): EPS=-1.35 | Chg30d=-102.63% | Revisions=-20% | GrowthEPS=+41.8% | GrowthRev=+4566.4%
[Analyst] Revisions Ratio: -33%